Pliant Therapeutics has a pipeline of experimental fibrosis treatments and a research alliance with Novartis. Now the biotech is preparing an IPO to raise cash to advance its clinical-stage programs.
In paperwork filed with securities regulators, Pliant set an $86 million... Read more »
Alexion Pharmaceuticals CEO Ludwig Hantson has made no secret that he wants to diversify his company’s drug portfolio and he has shown willingness to open the corporate checkbook to accomplish that goal.
Last October, Alexion (NASDAQ: ALXN) struck a $930... Read more »
Chimeric antigen receptor T-cell therapies have shown remarkable efficacy in leukemia and lymphoma patients who relapsed or were refractory to several prior treatments, but many challenges remain in the cancer cell therapy field. Strategies that may improve upon first-generation therapies were... Read more »
Remdesivir, the investigational Gilead Sciences antiviral drug, looks more likely than ever to become the first treatment authorized by the FDA to treat patients with COVID-19.
National Institute of Allergy and Infectious Diseases (NIAID) head Anthony Fauci praised the drug after... Read more »
Some former executives and investors behind the second gene therapy to win FDA approval are teaming up again. Their new company, Taysha Gene Therapies, is launching with $30 million in the bank and a plan to bring its first central nervous... Read more »
COVID-19’s spread has clamped down on a lot of economic activity, including the work of developing and testing new medicines. But the FDA isn’t showing signs of slowing down, at least when it comes to drugs filed for accelerated approval. The... Read more »
The start of a potentially big biomedical breakthrough is blooming within all of us. Drug research aiming to turn bacteria into microbiome therapies now spans programs aiming to address gut disorders, autism, cancer, and more.
Given the number of late-stage and... Read more »
Two new special reports on Xconomy Insight provide an expert view on how companies can sustain clinical trials during the COVID-19 crisis. “Decentralized Clinical Trials: The Call for a New Paradigm” and “Sustaining Clinical Research During the Crisis... Read more »
A growing number of drug developers are embracing artificial intelligence as a tool for finding new medicines. Lantern Pharma is betting the technology can also resurrect failed cancer drugs and it is now preparing an initial public stock offering to support... Read more »